MedTrace Logo

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

NCT02383212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 398

Last updated 2020-01-27

No results posted yet for this study

Summary

This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.

Conditions

Interventions

DRUG

Cemiplimab

RADIATION

Hypofractionated radiotherapy

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Carboplatin

DRUG

GM-CSF

DRUG

Paclitaxel

DRUG

Pemetrexed

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Management · Regeneron Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-02
Primary Completion
2019-11-18
Completion
2019-11-18

Countries

  • United States
  • Australia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383212 on ClinicalTrials.gov